Home LiteratureArticle Details
PMID: 10667496 Published · ppublish English Journal Article Multicenter Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels.

Critical care medicine ·Vol. 28 ·No. 1 ·2000-01-00 ·Pages 34-45

Larsson L, Li X, Edström L, Eriksson LI, Zackrisson H, Argentini C, Schiaffino S

Abstract

Long-term treatment with nondepolarizing neuromuscular blocking agents and corticosteroids in the intensive care unit is not benign, and an increasing number of patients with acute quadriplegic myopathy have been reported with increased use of these drugs. The purpose of this study was to investigate the mechanisms underlying acute quadriplegic myopathy. Percutaneous muscle biopsy samples were obtained, and electrophysiologic examinations were performed during the acute phase and during recovery in patients with acute quadriplegic myopathy. Regulation of muscle contraction and myofibrillar protein synthesis was studied using cell physiologic techniques, ultrasensitive electrophoresis, in situ hybridization, and histopathologic techniques. All patients were seen in the intensive care unit of different university hospitals. All patients were critically ill with sepsis. They had been given massive doses of corticosteroids in combination with variable doses of neuromuscular blocking agents. All patients developed paralysis of spinal nerve-innervated muscles. On the other hand, cranial nerve-innervated muscle and sensory and cognitive functions were well maintained after discontinuation of treatment with neuromuscular blocking agents. Muscle biopsy samples were obtained and electrophysiologic examinations were performed in all patients. The major observations in patients with acute quadriplegic myopathy were, as follows: a) a general decrease in myofibrillar protein content; b) specific but highly variable partial or complete loss of myosin and myosin-associated proteins; c) very low thick-filament/thin-filament protein ratios; d) absence of myosin messenger RNA; and e) a dramatically impaired muscle cell force-generating capacity in the acute phase of acute quadriplegic myopathy. During clinical improvement, normal expression of myosin messenger RNAs, reexpression of thick-filament proteins, and increased specific tension were observed. Acute quadriplegic myopathy is associated with a specific decrease in thick-filament proteins related to an altered transcription rate. Although the decreased content of thick-filament proteins is important for prolonged muscle weakness, it is not the primary cause of muscle paralysis in the acute stage, during which impaired muscle membrane excitability probably plays a more significant role. Several factors contribute to this condition, but the action of corticosteroids seems to be the predominant one, along with potentiation by neuromuscular blocking agents, immobilization, and probably also concurrent sepsis.

MeSH Terms
Acute Disease Adrenal Cortex Hormones/adverse effects Adult Aged Aged, 80 and over Case-Control Studies Child Drug Therapy, Combination Electromyography Female Humans Male Middle Aged Muscle Contraction/physiology Muscle, Skeletal/cytology,physiology,ultrastructure Muscular Diseases/chemically induced,genetics,physiopathology Myofibrils/metabolism Myosins/genetics,metabolism Neuromuscular Nondepolarizing Agents/adverse effects Quadriplegia/chemically induced,genetics,physiopathology RNA, Messenger/metabolism Respiration, Artificial Sepsis/complications,drug therapy
Chemicals
Adrenal Cortex Hormones Neuromuscular Nondepolarizing Agents RNA, Messenger Myosins
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Larsson L
Noll Physiological Research Center, Pennsylvania State University, University Park 16802-6900, USA. lgl5@psu.edu
Li X
Edström L
Eriksson L I
Zackrisson H
Argentini C
Schiaffino S
Article Info
Journal
Critical care medicine
Abbr.
Crit Care Med
ISSN
0090-3493
Published
2000-01-00
Pages
34-45
Language
English
Region
United States
NLM ID
0355501
Subset
IM
Grants
NCRR NIH HHS · M01-RR10732-03 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com